Histamine-releasing factor has a proinflammatory role in mouse models of asthma and allergy

Journal of Clinical Investigation

Volumn 122, Issue 1, 2012, Pages 218-228

  Kashiwakura, Jun Ichi ^a,b   Ando, Tomoaki ^a   Matsumoto, Kenji ^c   Kimura, Miho ^a,h   Kitaura, Jiro ^a,i   Matho, Michael H ^a   Zajonc, Dirk M ^a   Ozeki, Tomomitsu ^d   Ra, Chisei ^b   MacDonald, Susan M ^e   Siraganian, Reuben P ^f   Broide, David H ^g   Kawakami, Yuko ^a   Kawakami, Toshiaki ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b NIHON UNIVERSITY   (Japan)

^c NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d ULVAC INC   (Japan)

^e JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

^f NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PROTEIN GST H3; PROTEIN GST N19; PROTEIN HISTAMINE RELEASING FACTOR; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ALLERGY; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AND IMMUNOGLOBULIN STRUCTURE; ARTICLE; ASTHMA; CELL ACTIVATION; CONTROLLED STUDY; DIMERIZATION; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; MAST CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; RESPIRATORY TRACT INFLAMMATION; SKIN ANAPHYLAXIS;

ANIMALS; ASTHMA; BASOPHILS; DIMERIZATION; DISEASE MODELS, ANIMAL; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; INFLAMMATION MEDIATORS; MAST CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PASSIVE CUTANEOUS ANAPHYLAXIS; PROTEIN INTERACTION DOMAINS AND MOTIFS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855444627     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI59072     Document Type: Article

References (66)

1. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as "tunable"effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 2005;23:749-786. (Pubitemid 40563184)
2. Thueson DO, Speck LS, Lett-Brown MA, Grant JA. Histamine-releasing activity (HRA). I. Production by mitogen- or antigen-stimulated human mononuclear cells. J Immunol. 1979;123(2):626-632. (Pubitemid 9203401)
3. MacDonald SM. Histamine releasing factors. In: Razin E, Rivera J, eds. Signal Transduction in Mast Cells and Basophils. New York, New York, USA: Springer-Verlag; 1999:390-401.
4. MacDonald SM, Rafnar T, Langdon J, Lichtenstein LM. Molecular identification of an IgE-dependent histamine-releasing factor. Science. 1995;269(5224):688-690.
5. Bohm H, et al. The growth-related protein P23 of the Ehrlich ascites tumor: translational control, cloning and primary structure. Biochem Int. 1989;19(2):277-286. (Pubitemid 19216486)
6. Chitpatima ST, Makrides S, Bandyopadhyay R, Brawerman G. Nucleotide sequence of a major messenger RNA for a 21 kilodalton polypeptide that is under translational control in mouse tumor cells. Nucleic Acids Res. 1988;16(5):2350.
7. Li F, Zhang D, Fujise K. Characterization of fortilin, a novel antiapoptotic protein. J Biol Chem. 2001;276(50):47542-47549.
8. Bommer UA, Thiele BJ. The translationally controlled tumour protein (TCTP). Int J Biochem Cell Biol. 2004;36(3):379-385.
9. MacDonald SM. Histamine-releasing factors. Curr Opin Immunol. 1996;8(6):778-783. (Pubitemid 27007643)
10. Warner JA, Pienkowski MM, Plaut M, Norman PS, Lichtenstein LM. Identification of histamine releasing factor(s) in the late phase of cutaneous IgE-mediated reactions. J Immunol. 1986;136(7):2583-2587. (Pubitemid 16136843)
11. MacDonald SM, et al. Studies of IgE-dependent histamine releasing factors: heterogeneity of IgE. J Immunol. 1987;139(2):506-512. (Pubitemid 17104052)
12. MacDonald SM. Histamine Releasing Factors And Ige Heterogeneity. St Louis, Missouri, USA: Mosby-Year Book Inc; 1993.
13. Telerman A, Amson R. The molecular programme of tumour reversion: the steps beyond malignant transformation. Nat Rev Cancer. 2009;9(3):206-216.
14. Thiele H, Berger M, Skalweit A, Thiele BJ. Expression of the gene and processed pseudogenes encoding the human and rabbit translationally controlled tumour protein (TCTP). Eur J Biochem. 2000;267(17):5473-5481.
15. Guillaume E, et al. Cellular distribution of translationally controlled tumor protein in rat and human testes. Proteomics. 2001;1(7):880-889. (Pubitemid 33587413)
16. Bommer UA, et al. The mRNA of the translationally controlled tumor protein P23/TCTP is a highly structured RNA, which activates the dsRNA-dependent protein kinase PKR. RNA. 2002;8(4):478-496.
17. Tuynder M, et al. Biological models and genes of tumor reversion: cellular reprogramming through tpt1/TCTP and SIAH-1. Proc Natl Acad Sci U S A. 2002;99(23):14976-14981. (Pubitemid 35334595)
18. Cans C, et al. Translationally controlled tumor protein acts as a guanine nucleotide dissociation inhibitor on the translation elongation factor eEF1A. Proc Natl Acad Sci U S A. 2003;100(24):13892-13897. (Pubitemid 37499162)
19. Fleischer TC, Weaver CM, McAfee KJ, Jennings JL, Link AJ. Systematic identification and functional screens of uncharacterized proteins associated with eukaryotic ribosomal complexes. Genes Dev. 2006;20(10):1294-1307. (Pubitemid 43727590)
20. Langdon JM, Vonakis BM, MacDonald SM. Identification of the interaction between the human recombinant histamine releasing factor/translationally controlled tumor protein and elongation factor-1 delta (also known as eElongation factor-1B beta). Biochim Biophys Acta. 2004;1688(3):232-236. (Pubitemid 38438526)
21. Hsu YC, Chern JJ, Cai Y, Liu M, Choi KW. Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature. 2007;445(7129):785-788. (Pubitemid 46279709)
22. Dong X, Yang B, Li Y, Zhong C, Ding J. Molecular basis of the acceleration of the GDP-GTP exchange of human ras homolog enriched in brain by human translationally controlled tumor protein. J Biol Chem. 2009;284(35):23754-23764.
23. Zhang D, Li F, Weidner D, Mnjoyan ZH, Fujise K. Physical and functional interaction between myeloid cell leukemia 1 protein (MCL1) and Fortilin. The potential role of MCL1 as a fortilin chaperone. J Biol Chem. 2002;277(40):37430-37438.
24. Liu H, Peng HW, Cheng YS, Yuan HS, Yang-Yen HF. Stabilization and enhancement of the antiapoptotic activity of mcl-1 by TCTP. Mol Cell Biol. 2005;25(8):3117-3126. (Pubitemid 40464314)
25. Yang Y, et al. An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity. Oncogene. 2005;24(30):4778-4788. (Pubitemid 41076295)
26. Susini L, et al. TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ. 2008;15(8):1211-1220. (Pubitemid 351984751)
27. Rho SB, et al. Anti-apoptotic protein TCTP controls the stability of the tumor suppressor p53. FEBS Lett. 2011;585(1):29-35.
28. Gachet Y, Tournier S, Lee M, Lazaris-Karatzas A, Poulton T, Bommer UA. The growth-related, translationally controlled protein P23 has properties of a tubulin binding protein and associates transiently with microtubules during the cell cycle. J Cell Sci. 1999;112(pt 8):1257-1271. (Pubitemid 29218914)
29. Fenner BJ, Scannell M, Prehn JH. Expanding the substantial interactome of NEMO using protein microarrays. PLoS One. 2010;5(1):e8799.
30. Rid R, et al. H2O2-dependent translocation of TCTP into the nucleus enables its interaction with VDR in human keratinocytes: TCTP as a further module in calcitriol signalling. J Steroid Biochem Mol Biol. 2010;118(1-2):29-40.
31. Yarm FR. Plk phosphorylation regulates the microtubule-stabilizing protein TCTP. Mol Cell Biol. 2002;22(17):6209-6221. (Pubitemid 34857840)
32. Chen SH, et al. A knockout mouse approach reveals that TCTP functions as an essential factor for cell proliferation and survival in a tissue- or cell type-specific manner. Mol Biol Cell. 2007;18(7):2525-2532.
33. Koide Y, et al. Embryonic lethality of fortilin-null mutant mice by BMP-pathway overactivation. Biochim Biophys Acta. 2009;1790(5):326-338.
34. Wantke F, MacGlashan DW, Langdon JM, MacDonald SM. The human recombinant histamine releasing factor: functional evidence that it does not bind to the IgE molecule. J Allergy Clin Immunol. 1999;103(4):642-648. (Pubitemid 29295572)
35. Langdon JM, Schroeder JT, Vonakis BM, Bieneman AP, Chichester K, Macdonald SM. Histamine-releasing factor/translationally controlled tumor protein (HRF/TCTP)-induced histamine release is enhanced with SHIP-1 knockdown in cultured human mast cell and basophil models. J Leukoc Biol. 2008;84(4):1151-1158.
36. Inagaki N, Goto S, Yamasaki M, Nagai H, Koda A. Studies on vascular permeability increasing factors involved in 48-hour homologous PCA in the mouse ear. Int Arch Allergy Appl Immunol. 1986;80(3):285-290. (Pubitemid 16090215)
37. Wershil BK, Wang ZS, Gordon JR, Galli SJ. Recruitment of neutrophils during IgE-dependent cutaneous late phase reactions in the mouse is mast celldependent. Partial inhibition of the reaction with antiserum against tumor necrosis factor-alpha. J Clin Invest. 1991;87(2):446-453.
38. Nagai H, et al. TNF-alpha participates in an IgE-mediated cutaneous reaction in mast cell deficient, WBB6F1-W/Wv mice. Inflamm Res. 1996;45(3):136-140.
39. Hsu CL, Neilsen CV, Bryce PJ. IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS One. 2010;5(8):e11944.
40. Metz M, Grimbaldeston MA, Nakae S, Piliponsky AM, Tsai M, Galli SJ. Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev. 2007;217:304-328. (Pubitemid 46718153)
41. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol. 1999;17:255-281. (Pubitemid 29241125)
42. Williams CM, Galli SJ. Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J Exp Med. 2000;192(3):455-462. (Pubitemid 30629171)
43. Wills-Karp M, et al. Interleukin-13: central mediator of allergic asthma. Science. 1998;282(5397):2258-2261. (Pubitemid 29004074)
44. Grunig G, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. 1998;282(5397):2261-2263. (Pubitemid 29004075)
45. Walter DM, et al. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol. 2001;167(8):4668-4675. (Pubitemid 32954348)
46. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med. 1996;183(1):195-201. (Pubitemid 26028759)
47. Mathias CB, et al. IgE influences the number and function of mature mast cells, but not progenitor recruitment in allergic pulmonary inflammation. J Immunol. 2009;182(4):2416-2424.
48. Takeda K, et al. Development of eosinophilic airway inflammation and airway hyperresponsiveness in mast cell-deficient mice. J Exp Med. 1997;186(3):449-454. (Pubitemid 27332903)
49. Kim HY, DeKruyff RH, Umetsu DT. The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat Immunol. 2010;11(7):577-584.
50. Locksley RM. Asthma and allergic inflammation. Cell. 2010;140(6):777-783.
51. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275-290. (Pubitemid 32368037)
52. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity. 2005;23(1):41-51. (Pubitemid 41019656)
53. Turner H, Kinet JP. Signalling through the high-affinity IgE receptor Fc epsilonRI. Nature. 1999;402(6760 suppl):B24-B30.
54. Thaw P, Baxter NJ, Hounslow AM, Price C, Waltho JP, Craven CJ. Structure of TCTP reveals unexpected relationship with guanine nucleotide-free chaperones. Nat Struct Biol. 2001;8(8):701-704. (Pubitemid 32757930)
55. Hinojosa-Moya J, Xoconostle-Cazares B, Piedra-Ibarra E, Mendez-Tenorio A, Lucas WJ, Ruiz-Medrano R. Phylogenetic and structural analysis of translationally controlled tumor proteins. J Mol Evol. 2008;66(5):472-483.
56. Nuoffer C, Wu SK, Dascher C, Balch WE. Mss4 does not function as an exchange factor for Rab in endoplasmic reticulum to Golgi transport. Molecular biology of the cell. 1997;8(7):1305-1316. (Pubitemid 27310476)
57. Yoon T, Jung J, Kim M, Lee KM, Choi EC, Lee K. Identification of the self-interaction of rat TCTP/IgE-dependent histamine-releasing factor using yeast two-hybrid system. Arch Biochem Biophys. 2000;384(2):379-382. (Pubitemid 32012814)
58. Kim M, et al. Dimerization of translationally controlled tumor protein is essential for its cytokinelike activity. PLoS One. 2009;4(7):e6464.
59. Segal DM, Taurog JD, Metzger H. Dimeric immunoglobulin E serves as a unit signal for mast cell degranulation. Proc Natl Acad Sci U S A. 1977;74(7):2993-2997. (Pubitemid 8152181)
60. Kim M, et al. A protein transduction domain located at the NH2-terminus of human translationally controlled tumor protein for delivery of active molecules to cells. Biomaterials. 2011;32(1):222-230.
61. Nagahara H, et al. Transduction of full-length TAT fusion proteins into mammalian cells: TATp27Kip1 induces cell migration. Nat Med. 1998;4(12):1449-1452. (Pubitemid 28553472)
62. Yeh YC, et al. The effects of overexpression of histamine releasing factor (HRF) in a transgenic mouse model. PLoS One. 2010;5(6):e11077.
63. Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, Galli SJ. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol. 2005;167(3):835-848. (Pubitemid 41216366)
64. Ozeki T, et al. Surface-bound casein modulates the adsorption and activity of kinesin on SiO2 surfaces. Biophys J. 2009;96(8):3305-3318.
65. Kawakami T, et al. Tyrosine phosphorylation is required for mast cell activation by Fc epsilon RI cross-linking. J Immunol. 1992;148(11):3513-3519.
66. Nakano T, et al. Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal, and intravenous transfer into genetically mast cell-deficient W/Wv mice. Evidence that cultured mast cells can give rise to both connective tissue type and mucosal mast cells. J Exp Med. 1985;162(3):1025-1043. (Pubitemid 16248206)